EA201492242A1 - Энхансеры продуцирующих клеточных линий - Google Patents
Энхансеры продуцирующих клеточных линийInfo
- Publication number
- EA201492242A1 EA201492242A1 EA201492242A EA201492242A EA201492242A1 EA 201492242 A1 EA201492242 A1 EA 201492242A1 EA 201492242 A EA201492242 A EA 201492242A EA 201492242 A EA201492242 A EA 201492242A EA 201492242 A1 EA201492242 A1 EA 201492242A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cell
- producing cell
- cell lines
- edem2
- enhancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Настоящее изобретение относится к открытию влияния эктопической экспрессии EDEM2 в продуцирующей клетке на улучшение выхода применяемого мультисубъединичного белка. Таким образом, в настоящем изобретении предлагаются продуцирующие клеточные линии, такие как каноническая биофармацевтическая продуцирующая клетка млекопитающего - клетка СНО, содержащая рекомбинантные полинуклеотиды, кодирующие EDEM2. Также раскрыта продуцирующая клетка, содержащая как EDEM2-кодирующий полинуклеотид, так и ХВР1-кодирующий полинуклеотид. Раскрыты улучшенные титры антител, продуцированных этими клеточными линиями, а также улучшенные клеточные плотности, приобретенные этими клетками в культуре.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261652549P | 2012-05-29 | 2012-05-29 | |
US61/652,549 | 2012-05-29 | ||
US13/904,587 | 2013-05-29 | ||
US13/904,587 US9079954B2 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
PCT/US2013/043116 WO2013181253A1 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201492242A1 true EA201492242A1 (ru) | 2015-05-29 |
EA028790B1 EA028790B1 (ru) | 2017-12-29 |
Family
ID=49670701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792213A EA201792213A1 (ru) | 2012-05-29 | 2013-05-29 | Энхансеры продуцирующих клеточных линий |
EA201492242A EA028790B1 (ru) | 2012-05-29 | 2013-05-29 | Энхансеры продуцирующих клеточных линий |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792213A EA201792213A1 (ru) | 2012-05-29 | 2013-05-29 | Энхансеры продуцирующих клеточных линий |
Country Status (21)
Country | Link |
---|---|
US (9) | US9079954B2 (ru) |
EP (3) | EP3564262A1 (ru) |
JP (5) | JP6298455B2 (ru) |
KR (3) | KR102126210B1 (ru) |
CN (2) | CN110835624A (ru) |
AU (4) | AU2013267525B2 (ru) |
BR (1) | BR112014029095A2 (ru) |
CA (1) | CA2873131A1 (ru) |
DK (1) | DK2875047T3 (ru) |
EA (2) | EA201792213A1 (ru) |
ES (1) | ES2940900T3 (ru) |
FI (1) | FI2875047T3 (ru) |
HK (1) | HK1205137A1 (ru) |
HU (1) | HUE061479T2 (ru) |
IL (3) | IL235573B (ru) |
MX (1) | MX360359B (ru) |
PL (1) | PL2875047T3 (ru) |
SG (2) | SG10201606654XA (ru) |
TW (2) | TWI641687B (ru) |
WO (1) | WO2013181253A1 (ru) |
ZA (1) | ZA201408289B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
BR112018071283A2 (pt) | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
KR20180134894A (ko) | 2016-04-20 | 2018-12-19 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
CN116327963A (zh) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
CA3067735A1 (en) | 2017-08-17 | 2019-02-21 | Just Biotherapeutics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60211329T2 (de) | 2001-01-16 | 2007-05-24 | Regeneron Pharmaceuticals, Inc. | Isolierung von sezernierte proteine exprimierenden zellen |
CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
EP1572944A4 (en) | 2002-08-30 | 2007-12-26 | Harvard College | METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF XBP-1 |
AU2004248165A1 (en) | 2003-06-11 | 2004-12-23 | Biogen Idec Ma Inc. | Method to increase protein production in culture |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
JP2007537728A (ja) * | 2004-03-31 | 2007-12-27 | セントカー・インコーポレーテツド | タンパク質生産速度の変更方法 |
DK1781698T3 (en) | 2004-07-20 | 2016-10-03 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE USE OF Angiopoietin-like-4-PROTEIN |
ES2653843T3 (es) * | 2004-09-02 | 2018-02-09 | Wyeth Llc | Sistemas y procedimientos de producción de proteínas |
AU2005284798B2 (en) * | 2004-09-15 | 2012-02-02 | The President And Fellows Of Harvard College | Reducing ER stress in the treatment of obesity and diabetes |
EP1964922A1 (en) * | 2007-03-02 | 2008-09-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
EP2129685B1 (en) | 2007-03-21 | 2013-11-20 | Danisco US Inc. | Over expression of foldases and chaperones improves protein production |
EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
EP2209891A1 (en) | 2007-11-13 | 2010-07-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improving the secretory capacity in host cells |
US20090247609A1 (en) * | 2007-12-20 | 2009-10-01 | Hitto Kaufmann | Sm-protein based secretion engineering |
CA2726289A1 (en) | 2008-05-28 | 2009-12-23 | Bayer Healthcare Llc | Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells |
US20110142799A1 (en) | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
GB0902180D0 (en) | 2009-02-10 | 2009-03-25 | Ucb Pharma Sa | Method for producing protein |
US8722046B2 (en) * | 2009-04-08 | 2014-05-13 | The United States Of America As Represented By The Secretary Of The Army | Human monoclonal antibodies protective against bubonic plague |
KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
JO3274B1 (ar) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
-
2013
- 2013-05-28 TW TW102118721A patent/TWI641687B/zh active
- 2013-05-28 TW TW107107833A patent/TW201823460A/zh unknown
- 2013-05-29 EP EP19177521.2A patent/EP3564262A1/en not_active Withdrawn
- 2013-05-29 ES ES13729169T patent/ES2940900T3/es active Active
- 2013-05-29 SG SG10201606654XA patent/SG10201606654XA/en unknown
- 2013-05-29 EA EA201792213A patent/EA201792213A1/ru unknown
- 2013-05-29 US US13/904,587 patent/US9079954B2/en active Active
- 2013-05-29 CN CN201911104558.3A patent/CN110835624A/zh active Pending
- 2013-05-29 EP EP22214230.9A patent/EP4219546A3/en active Pending
- 2013-05-29 KR KR1020147033930A patent/KR102126210B1/ko active IP Right Grant
- 2013-05-29 MX MX2014014630A patent/MX360359B/es active IP Right Grant
- 2013-05-29 HU HUE13729169A patent/HUE061479T2/hu unknown
- 2013-05-29 WO PCT/US2013/043116 patent/WO2013181253A1/en active Application Filing
- 2013-05-29 DK DK13729169.6T patent/DK2875047T3/da active
- 2013-05-29 AU AU2013267525A patent/AU2013267525B2/en active Active
- 2013-05-29 KR KR1020207017417A patent/KR102346867B1/ko active IP Right Grant
- 2013-05-29 PL PL13729169.6T patent/PL2875047T3/pl unknown
- 2013-05-29 SG SG11201407652RA patent/SG11201407652RA/en unknown
- 2013-05-29 CA CA2873131A patent/CA2873131A1/en active Pending
- 2013-05-29 EP EP13729169.6A patent/EP2875047B1/en active Active
- 2013-05-29 KR KR1020217043208A patent/KR102528950B1/ko active IP Right Grant
- 2013-05-29 CN CN201380028164.9A patent/CN104350068B/zh active Active
- 2013-05-29 EA EA201492242A patent/EA028790B1/ru not_active IP Right Cessation
- 2013-05-29 BR BR112014029095A patent/BR112014029095A2/pt not_active Application Discontinuation
- 2013-05-29 JP JP2015515154A patent/JP6298455B2/ja active Active
- 2013-05-29 FI FIEP13729169.6T patent/FI2875047T3/fi active
-
2014
- 2014-11-09 IL IL235573A patent/IL235573B/en active IP Right Grant
- 2014-11-12 ZA ZA2014/08289A patent/ZA201408289B/en unknown
- 2014-11-26 US US14/555,220 patent/US9382315B2/en active Active
-
2015
- 2015-06-11 US US14/737,090 patent/US10227401B2/en active Active
- 2015-06-12 HK HK15105590.6A patent/HK1205137A1/xx unknown
- 2015-06-29 US US14/754,146 patent/US9228012B2/en active Active
- 2015-06-29 US US14/754,112 patent/US9193786B2/en active Active
-
2016
- 2016-07-01 US US15/201,104 patent/US9688751B2/en not_active Ceased
-
2017
- 2017-06-16 US US15/624,982 patent/US10351622B2/en active Active
-
2018
- 2018-02-14 AU AU2018201094A patent/AU2018201094B2/en active Active
- 2018-02-23 JP JP2018030324A patent/JP6622334B2/ja active Active
-
2019
- 2019-04-07 IL IL265867A patent/IL265867A/en unknown
- 2019-04-17 US US16/387,134 patent/USRE48651E1/en active Active
- 2019-05-21 US US16/417,792 patent/US10611831B2/en active Active
- 2019-05-30 AU AU2019203780A patent/AU2019203780B2/en active Active
- 2019-11-21 JP JP2019210124A patent/JP7037535B2/ja active Active
-
2021
- 2021-01-03 IL IL279922A patent/IL279922A/en unknown
- 2021-10-01 AU AU2021240303A patent/AU2021240303A1/en active Pending
- 2021-12-27 JP JP2021212131A patent/JP7382383B2/ja active Active
-
2023
- 2023-08-22 JP JP2023134346A patent/JP2023153268A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201492242A1 (ru) | Энхансеры продуцирующих клеточных линий | |
EA201400709A1 (ru) | Молекула биспецифического антитела | |
EA201490216A1 (ru) | Варианты альфа-амилазы и кодирующие их полинуклеотиды | |
EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
EA201590068A1 (ru) | Сайт-специфическая интеграция | |
MX2013007853A (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
BR112016004413A2 (pt) | composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio | |
IN2014CN04586A (ru) | ||
IN2015DN01606A (ru) | ||
BR112014026308A2 (pt) | composições de cultura celular e métodos para produção de polipeptídeos | |
MX337919B (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
MY181688A (en) | Improved production of fatty acid derivatives | |
EA201691109A1 (ru) | Химерные и гибридные полипептиды фактора viii-fc и способы их применения | |
SG10201900948PA (en) | Modified nucleotide linkers | |
EA201490568A1 (ru) | Варианты глюкоамилазы и кодирующие их полинуклеотиды | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
BR112017027527A2 (pt) | ?método para a produção de feromônios de mariposas em levedura | |
MX2015000312A (es) | Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican. | |
EA201590550A1 (ru) | Композиции и способы получения гликопротеинов | |
MX2013004892A (es) | Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos. | |
EA201491144A1 (ru) | Способ флокуляции | |
MX349517B (es) | Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos. | |
MX2014001594A (es) | Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican. | |
BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
EA201990034A1 (ru) | Ферментативное гликозилирование стевиолгликозидов и других соединений с глюкозо-1-фосфатом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG TJ TM |